Search Results for: 68

Clinical Study of SYN-010, for the Treatment of IBS-C ROCKVILLE, Md., Jan. 3, 2019 /PRNewswire/ — Synthetic Biologics, Inc. (NYSE American: SYN), a late-stage clinical company developing therapeutics designed to preserve the microbiome to protect and restore the health of patients, today announced that the first two patients have been enrolled in SYN-010’s Phase 2b investigator-sponsored clinical […]

— Announced Agreement with Cedars-Sinai Medical Center to Co-fund a Phase 2b Investigator-Sponsored Clinical Study of SYN-010, for the Treatment of IBS-C — — Strengthened Balance Sheet in Support of Microbiome-Focused Clinical Development Programs — — Conference Call Today, November 8, 2018, at 4:30 p.m. (EST) — ROCKVILLE, Md., Nov. 8, 2018 /PRNewswire/ — Synthetic Biologics,

— Conference Call Scheduled for Thursday, November 8, 2018 at 4:30 p.m. EDT — ROCKVILLE, Md., Oct. 30, 2018 /PRNewswire/ — Synthetic Biologics, Inc. (NYSE American: SYN), a late-stage clinical company developing therapeutics that preserve the microbiome to protect and restore the health of patients, announced today that the Company intends to release its operational highlights

— Conference Call Scheduled for Wednesday, August 8, 2018 at 4:30 p.m. EDT — ROCKVILLE, Md., July 31, 2018 /PRNewswire/ — Synthetic Biologics, Inc. (NYSE American: SYN), a late-stage clinical company developing therapeutics that preserve the microbiome to protect and restore the health of patients, announced today that the Company intends to release its operational

— Conference Call Scheduled for Tuesday, May 8, 2018 at 4:30 p.m. EDT — ROCKVILLE, Md., April 26, 2018 /PRNewswire/ — Synthetic Biologics, Inc. (NYSE American: SYN), a late-stage clinical company developing therapeutics that preserve the microbiome to protect and restore the health of patients, announced today that the Company intends to release its operational highlights

— Strengthened Balance Sheet in Support of Microbiome-Focused Clinical Development Programs — — Held Initial Type-B Multidisciplinary Meeting with FDA to Discuss Late-Stage Clinical Advancement for SYN-004 (ribaxamase) — — Conference Call Today, November 1, 2017, at 4:30 p.m. EDT — ROCKVILLE, Md., Nov. 1, 2017 /PRNewswire/ — Synthetic Biologics, Inc. (NYSE American: SYN), a late-stage

— SYN-004 (ribaxamase) Receives Breakthrough Therapy Designation from FDA for Prevention of CDI — — Three Ribaxamase Presentations to be Included at Infectious Disease Week™ (ID Week) 2017 — — Conference Call Today, August 3, 2017, at 8:30 a.m. EDT — ROCKVILLE, Md., Aug. 3, 2017 /PRNewswire/ — Synthetic Biologics, Inc. (NYSE American: SYN), a late-stage

ROCKVILLE, Md., Dec. 1, 2016 /PRNewswire/ — Synthetic Biologics, Inc. (NYSE MKT: SYN), a late-stage clinical company developing therapeutics focused on the gut microbiome, today announced that members of Synthetic Biologics’ executive leadership team will participate in two upcoming investor conferences: 2016 Jefferies Annual Microbiome Summit London, EnglandTuesday, December 13, 2016 Guggenheim Securities 4th Annual Boston Healthcare

— Completed Enrollment of Phase 2b Proof-of-Concept Clinical Trial for the Prevention of C. difficile Infection (CDI), Antibiotic-Associated Diarrhea (AAD) and the Emergence of Antibiotic-Resistant Organisms — — Awarded Research Contract from Centers for Disease Control and Prevention to Determine SYN-004’s (ribaxamase) Ability to Prevent Antibiotic-Resistance in the Gut Microbiome — — Conference Call Today,

– Held End of Phase 2 Meeting with FDA and Received Guidance for Advancement to First Pivotal Trial for SYN-010, for the Treatment of Irritable Bowel Syndrome with Constipation (IBS-C) – – Company Provides Update on Enrollment for Phase 2b Proof-of-Concept Clinical Trial for SYN-004 (ribaxamase), for the Prevention of C. Difficile Infection (CDI) and